Mylan gets October date for US Advair

The US Food and Drug Administration (FDA) has assigned Mylan a revised goal date for regulatory action on the firm’s generic Advair (fluticasone/salmeterol) dossier in mid-October. That date is three months after the company in mid-July this year responded to a complete response letter (CRL) that the FDA had sent towards the end of June, around the time of the 27 June previous target action date for Mylan’s application (Generics bulletin, 22 June 2018, page 1).

The US Food and Drug Administration (FDA) has assigned Mylan a revised goal date for regulatory action on the firm’s generic Advair (fluticasone/salmeterol) dossier in mid-October. That date is three months after the company in mid-July this year responded to a complete response letter (CRL) that the FDA had sent towards the end of June, around the time of the 27 June previous target action date for Mylan’s application (Generics bulletin, 22 June 2018, page 1).

Stressing that the CRL had “only included labelling and chemistry, manufacturing and controls (CMC) comments”, Mylan’s president, Rajiv Malik, told...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin